Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avalo Therapeutics, Inc.AVTX · Entity 4936 | Director · Chief Executive Officer | October 01, 2021 | October 04, 2021 |
| Phathom Pharmaceuticals, Inc.PHAT · Entity 5177 | Director | May 19, 2026 | May 21, 2026 |
| Vanda Pharmaceuticals Inc.VNDA · Entity 5861 | Director | June 13, 2019 | June 17, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avalo Therapeutics, Inc.
Report date October 01, 2021 · Filed October 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2031-10-01 | Direct | 78,116 |
Reported balance
After 2021-10-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-10-01 · Grant · Acquired 78,116 · Balance 78,116 F1: 100% of this stock option will immediately vest on the date that it is granted. If employment is terminated prior to the end of the calendar quarter in which the option was granted, the number of shares underlying such stock option that reflects the percentage of calendar days remaining in such calendar quarter after such employment termination date shall be forfeited and deemed cancelled. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of this stock option will immediately vest on the date that it is granted. If employment is terminated prior to the end of the calendar quarter in which the option was granted, the number of shares underlying such stock option that reflects the percentage of calendar days remaining in such calendar quarter after such employment termination date shall be forfeited and deemed cancelled.
Phathom Pharmaceuticals, Inc.
Report date May 19, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 63,920 |
Reported balance
After 2026-05-19 transaction · row 1
1 source rowRow 1 · 2026-05-19 · Grant · Acquired 24,122 · Balance 63,920 F1: The Restricted Stock Units ("RSUs") were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units ("RSUs") were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
Vanda Pharmaceuticals Inc.
Report date June 13, 2019 · Filed June 17, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,000 |
Reported balance
After 2019-06-13 transaction · row 1
1 source rowRow 1 · 2019-06-13 · Grant · Acquired 5,000 · Balance 15,000 F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 13, 2020, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.04 · Expires 2029-06-12 | Direct | 10,000 |
Reported balance
After 2019-06-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-06-13 · Grant · Acquired 10,000 · Balance 10,000 F2: This option vests and becomes exercisable with respect to 100% of the option shares on June 13, 2020, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 13, 2020, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.
F2: This option vests and becomes exercisable with respect to 100% of the option shares on June 13, 2020, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aevi Genomic Medicine, LLC
Report date June 09, 2020 · Filed June 11, 2020
Section 16 reporting ended · disclosed 2020-02-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 175,746 |
Reported balance
After 2020-06-09 transaction · row 1
1 source rowRow 1 · 2020-06-09 · Purchase · Acquired 100,000 · Balance 175,746 |
Sage Therapeutics, Inc.
Report date July 31, 2025 · Filed July 31, 2025
Section 16 reporting ended · disclosed 2025-07-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.77 · Expires 2035-06-10 | Direct | 0 |
Reported balance
After 2025-07-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-07-31 · Disposition to issuer · Disposed 21,500 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer to purchase all outstanding shares of common stock of the Issuer (each, a "Share") for (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes, and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). F2: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025. F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer to purchase all outstanding shares of common stock of the Issuer (each, a "Share") for (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes, and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time").
F2: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025.
F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 19, 2026 Filed May 21, 2026 20:30 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 24,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-234566 · ownership.xml · nonDerivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,920 F1 · shares: The Restricted Stock Units ("RSUs") were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| July 31, 2025 Filed Jul 31, 2025 15:52 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | Disposition to issuerStock Option (Right to Buy) · Derivative | 21,500 | Not disclosed Strike: $6.77 | Not disclosed |
DisclosureSEC source: 0000950170-25-100680 · ownership.xml · derivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,500 shares Expires 2035-06-10 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer to purchase all outstanding shares of common stock of the Issuer (each, a "Share") for (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes, and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). F2 · kind: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:13 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | GrantStock Option (Right to Buy) · Derivative | 21,500 | $0.00 Strike: $6.77 | $0.00 |
DisclosureSEC source: 0001562180-25-004788 · primarydocument.xml · derivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,500 Underlying: Common Stock · 21,500 shares Expires 2035-06-11 F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan in accordance with Sage's Non-Employee Director Compensation Program. The option will vest in full upon the earlier to occur of June 11, 2026 or the day immediately prior to the 2026 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 20:58 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0000950170-25-082456 · ownership.xml · derivative · entry 2 COLA MICHAEL F · CIK 0001188940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2035-06-02 F2 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 20:58 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-082456 · ownership.xml · nonDerivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,798 F1 · shares: The Restricted Stock Units ("RSUs") were granted on June 3, 2025, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 20:57 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $10.90 | $0.00 |
DisclosureSEC source: 0001562180-24-004949 · primarydocument.xml · derivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-06-09 F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan in accordance with Sage's Non-Employee Director Compensation Program. The option will vest in full upon the earlier to occur of June 10, 2025 or the day immediately prior to the 2025 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date. Read SEC document |
| May 23, 2024 Filed May 24, 2024 23:44 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $10.30 | $0.00 |
DisclosureSEC source: 0000950170-24-064830 · ownership.xml · derivative · entry 2 COLA MICHAEL F · CIK 0001188940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2034-05-22 F2 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date. Read SEC document |
| May 23, 2024 Filed May 24, 2024 23:44 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-064830 · ownership.xml · nonDerivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,298 F1 · shares: The Restricted Stock Units ("RSUs") were granted on May 23, 2024, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:05 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $56.10 | $0.00 |
DisclosureSEC source: 0001562180-23-005258 · primarydocument.xml · derivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-06-15 F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 15, 2024 or the day immediately prior to the 2024 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date. Read SEC document |
| May 25, 2023 Filed May 30, 2023 22:46 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $11.72 | $0.00 |
DisclosureSEC source: 0001209191-23-033004 · doc4.xml · derivative · entry 2 COLA MICHAEL F · CIK 0001188940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-05-24 F2 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing in service on the Board through such vesting date. Read SEC document |
| May 25, 2023 Filed May 30, 2023 22:46 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033004 · doc4.xml · nonDerivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,798 F1 · shares: The Restricted Stock Units ("RSUs") were granted on May 25, 2023, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:36 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | GrantStock Option (Right to Buy) · Derivative | 9,947 | $0.00 Strike: $31.36 | $0.00 |
DisclosureSEC source: 0001562180-22-005206 · primarydocument.xml · derivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,947 Underlying: Common Stock · 9,947 shares Expires 2032-06-16 F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 16, 2023 or the day immediately prior to the 2023 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:39 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $7.40 | $0.00 |
DisclosureSEC source: 0001209191-22-032574 · doc4.xml · derivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-05-24 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 20:28 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 78,116 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0001878894-21-000003 · edgar.xml · derivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,116 Underlying: Common Stock · 78,116 shares Expires 2031-10-01 F1 · shares: 100% of this stock option will immediately vest on the date that it is granted. If employment is terminated prior to the end of the calendar quarter in which the option was granted, the number of shares underlying such stock option that reflects the percentage of calendar days remaining in such calendar quarter after such employment termination date shall be forfeited and deemed cancelled. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 20:44 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 51,740 | $0.00 Strike: $3.39 | $0.00 |
DisclosureSEC source: 0001192482-21-000611 · edgar.xml · derivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,740 Underlying: Common Stock · 51,740 shares Expires 2031-07-01 F1 · shares: 100% of this stock option will immediately vest on the date that it is granted. If employment is terminated prior to the end of the calendar quarter in which the option was granted, the number of shares underlying such stock option that reflects the percentage of calendar days remaining in such calendar quarter after such employment termination date shall be forfeited and deemed cancelled. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 20:11 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $76.09 | $0.00 |
DisclosureSEC source: 0001562180-21-004208 · primarydocument.xml · derivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-10 F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 10, 2022 or the day immediately prior to the 2022 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date. Read SEC document |
| May 21, 2021 Filed May 24, 2021 21:39 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $35.49 | $0.00 |
DisclosureSEC source: 0001209191-21-035470 · doc4.xml · derivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2031-05-20 F1 · derivative.exercise_date: The option was granted pursuant to the Registrant's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Registrant's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 22:40 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 70,881 | $0.00 Strike: $3.05 | $0.00 |
DisclosureSEC source: 0001192482-21-000303 · edgar.xml · derivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,881 Underlying: Common Stock · 70,881 shares Expires 2031-04-01 F1 · shares: 100% of this stock option will immediately vest on the date that it is granted. If employment is terminated prior to the end of the calendar quarter in which the option was granted, the number of shares underlying such stock option that reflects the percentage of calendar days remaining in such calendar quarter after such employment termination date shall be forfeited and deemed cancelled. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 21:08 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 850,000 | $0.00 Strike: $3.32 | $0.00 |
DisclosureSEC source: 0001192482-21-000119 · edgar.xml · derivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 850,000 Underlying: Common Stock · 850,000 shares Expires 2031-01-26 F1 · derivative.exercise_date: The stock option will vest over four years, with the first 25% vesting on the first anniversary of the grant date, and the remainder vesting in equal monthly installments over the following 36 months, subject to the reporting person's continued service on each such vesting date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:47 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 64,798 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001192482-21-000047 · edgar.xml · derivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,798 Underlying: Common Stock · 64,798 shares Expires 2031-01-04 F1 · shares: 100% of this stock option will immediately vest on the date that it is granted. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 20:02 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 76,674 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001192482-20-000761 · edgar.xml · derivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,674 Underlying: Common Stock · 76,674 shares Expires 2030-10-01 F1 · shares: 100% of this stock option will immediately vest on the date that it is granted. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 20:28 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 64,683 | $0.00 Strike: $2.56 | $0.00 |
DisclosureSEC source: 0001192482-20-000604 · edgar.xml · derivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,683 Underlying: Common Stock · 64,683 shares Expires 2030-07-01 F1 · shares: 100% of this stock option will immediately vest on the date that it is granted. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 20:05 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 84,322 | $0.00 Strike: $2.51 | $0.00 |
DisclosureSEC source: 0001192482-20-000554 · edgar.xml · derivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,322 Underlying: Common Stock · 84,322 shares Expires 2030-06-18 F1 · shares: 100% of this stock option will immediately vest on the date that it is granted. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 20:15 UTC | Aevi Genomic Medicine, LLC CERC · Entity 148532 | PurchaseCommon Stock | 100,000 | $2.50 | $250,000.00 |
DisclosureSEC source: 0001192482-20-000475 · edgar.xml · nonDerivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,746 Read SEC document |
| June 09, 2020 Filed Jun 12, 2020 00:28 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | PurchaseCommon Stock | 100,000 | $2.50 | $250,000.00 |
DisclosureSEC source: 0001192482-20-000477 · edgar.xml · nonDerivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,746 Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 20:18 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $36.47 | $0.00 |
DisclosureSEC source: 0001562180-20-004426 · primarydocument.xml · derivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-06-09 F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 9, 2021 or the day immediately prior to the 2021 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date. Read SEC document |
| May 21, 2020 Filed May 22, 2020 21:01 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option · Derivative | 10,000 | $0.00 Strike: $36.85 | $0.00 |
DisclosureSEC source: 0001209191-20-031794 · doc4.xml · derivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-05-20 F1 · derivative.exercise_date: The option was granted pursuant to the Registrant's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Registrant's stockholders, subject to Michael Cola continuing in service on the Board through such vesting date. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 16:13 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | Disposition to issuerWarrant (Right to Buy) · Derivative | 21,181 | $0.00 Strike: $2.84 | $0.00 |
DisclosureSEC source: 0001192482-20-000111 · edgar.xml · derivative · entry 10 COLA MICHAEL F · CIK 0001188940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,181 shares Expires 2022-10-17 F10 · derivative.exercise_date: This warrant, which was issued pursuant to a Securities Purchase Agreement dated August 9, 2017, was subsequently amended by the Amendment Agreement of Warrants to Purchase Common Stock dated December 5, 2019, whereby immediately prior to the Merger the warrants were automatically exercised in a cashless exercise. Given the exercise price of the outstanding warrants, the cashless exercise resulted in no shares of common stock being issued and the warrant was rendered null and void. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 16:13 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | Disposition to issuerStock Option (Right to Purchase) · Derivative | 1,500,000 | $0.00 Strike: $4.22 | $0.00 |
DisclosureSEC source: 0001192482-20-000111 · edgar.xml · derivative · entry 9 COLA MICHAEL F · CIK 0001188940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500,000 shares Expires 2023-09-13 F9 · derivative.exercise_date: This option which became exercisable on September 13, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 16:13 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | Disposition to issuerStock Option (Right to Purchase) · Derivative | 50,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001192482-20-000111 · edgar.xml · derivative · entry 8 COLA MICHAEL F · CIK 0001188940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2027-08-11 F8 · derivative.exercise_date: This option, which became exercisable on August 11, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 16:13 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | Disposition to issuerStock Option (Right to Purchase) · Derivative | 661,000 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001192482-20-000111 · edgar.xml · derivative · entry 7 COLA MICHAEL F · CIK 0001188940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 661,000 shares Expires 2028-04-17 F7 · derivative.exercise_date: This option, which became exercisable on April 17, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 16:13 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | Disposition to issuerStock Option (Right to Purchase) · Derivative | 450,000 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0001192482-20-000111 · edgar.xml · derivative · entry 6 COLA MICHAEL F · CIK 0001188940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 450,000 shares Expires 2028-05-14 F6 · derivative.exercise_date: This option, which became exercisable on May 14, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 16:13 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | Disposition to issuerStock Option (Right to Purchase) · Derivative | 250,000 | $0.00 Strike: $4.91 | $0.00 |
DisclosureSEC source: 0001192482-20-000111 · edgar.xml · derivative · entry 5 COLA MICHAEL F · CIK 0001188940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2027-02-17 F5 · derivative.exercise_date: This option, which became exercisable on February 17, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 16:13 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | Disposition to issuerStock Option (Right to Purchase) · Derivative | 250,000 | $0.00 Strike: $4.83 | $0.00 |
DisclosureSEC source: 0001192482-20-000111 · edgar.xml · derivative · entry 4 COLA MICHAEL F · CIK 0001188940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2026-04-15 F4 · derivative.exercise_date: This option, which became exercisable on April 15, 2017, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 16:13 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | Disposition to issuerStock Option (Right to Purchase) · Derivative | 292,087 | $0.00 Strike: $7.01 | $0.00 |
DisclosureSEC source: 0001192482-20-000111 · edgar.xml · derivative · entry 3 COLA MICHAEL F · CIK 0001188940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 292,087 shares Expires 2025-02-18 F3 · derivative.exercise_date: This option, which became exercisable on February 18, 2015, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 16:13 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | Disposition to issuerStock Option (Right to Purchase) · Derivative | 17,327 | $0.00 Strike: $6.45 | $0.00 |
DisclosureSEC source: 0001192482-20-000111 · edgar.xml · derivative · entry 2 COLA MICHAEL F · CIK 0001188940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,327 shares Expires 2024-04-16 F2 · derivative.exercise_date: This option, which became exercisable on April 16, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 16:13 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | Disposition to issuerCommon Stock | 2,267,859 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-20-000111 · edgar.xml · nonDerivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of as a result of the merger pursuant to the previously announced Agreement and Plan of Merger and Reorganization by and among Cerecor Inc. ("Cerecor"), Genie Merger Sub, Inc., Second Genie Merger Sub, LLC and issuer (the "Merger"). At the effective time of the Merger, holders of issuer common stock received (A) the fraction of a share of Cerecor common stock equal to the exchange ratio of 0.0334 (B) one contingent value right, which represents the right to receive contingent payments upon the achievement of certain milestones and (C) cash in lieu of any fractional shares of Cerecor common stock. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:38 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 1,200,000 | $0.00 Strike: $3.98 | $0.00 |
DisclosureSEC source: 0001104659-20-011268 · tm206826d3_4.xml · derivative · entry 2 COLA MICHAEL F · CIK 0001188940 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200,000 Underlying: Common Stock · 1,200,000 shares Expires 2030-02-03 F2 · derivative.exercise_date: The stock option will vest over four years, with the first 25% vesting on the first anniversary of the grant date, and the remainder vesting in equal monthly installments, subject to the reporting person's continued service on each such vesting date. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:38 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantCommon Stock | 75,746 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-011268 · tm206826d3_4.xml · nonDerivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,746 F1 · price: Received in exchange for 2,267,859 shares of Aevi Genomic Medicine, Inc. ("Aevi") common stock in connection with the merger of Aevi into a wholly owned subsidiary of the issuer pursuant to the previously announced Agreement and Plan of Merger and Reorganization by and among Aevi, Genie Merger Sub, Inc., Second Merger Sub, LLC and the issuer. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 21:15 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | PurchaseCommon Stock | 2,049,376 | $0.13 | $274,616.38 |
DisclosureSEC source: 0001192482-19-000513 · edgar.xml · nonDerivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,267,859 Read SEC document |
| October 29, 2019 Filed Feb 19, 2022 00:34 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | PurchaseCommon Stock | 9,798 | $19.00 | $186,162.00 |
DisclosureSEC source: 0001209191-22-011484 · doc4.xml · nonDerivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,798 Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 21:02 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $15.04 | $0.00 |
DisclosureSEC source: 0001209191-19-037410 · doc4.xml · derivative · entry 2 COLA MICHAEL F · CIK 0001188940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-12 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 100% of the option shares on June 13, 2020, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 21:02 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-037410 · doc4.xml · nonDerivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 13, 2020, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 20:02 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $177.41 | $0.00 |
DisclosureSEC source: 0001562180-19-003390 · primarydocument.xml · derivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-05 F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 5, 2020 or the day immediately prior to the 2020 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 16:27 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | GrantStock Option (Right to Purchase) · Derivative | 661,000 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001192482-18-000304 · edgar.xml · derivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 661,000 Underlying: Common Stock · 661,000 shares Expires 2028-04-17 F1 · date: The option award was granted on April 17, 2018 and was subject to forfeiture if stockholder approval of a proposed amendment to the Issuer's stock incentive plan to increase the number of shares reserved for issuance under the plan was not obtained. The Issuer's stockholders approved the amendment to the Issuer's stock incentive plan at the Issuer's annual meeting of stockholders on June 14, 2018. F2 · derivative.exercise_date: The option award vests and becomes exercisable as follows (rounded up to the nearest whole share of common stock): one-third on April 17, 2019, then in 24 equal monthly installments on the 17th day of each subsequent calendar month, subject to the reporting person's continued service with the issuer. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 20:32 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $18.30 | $0.00 |
DisclosureSEC source: 0000899243-18-016772 · doc4.xml · derivative · entry 2 COLA MICHAEL F · CIK 0001188940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-12 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 100% of the option shares on June 13, 2019, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 20:32 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-016772 · doc4.xml · nonDerivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 13, 2019, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 20:03 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $154.06 | $0.00 |
DisclosureSEC source: 0001562180-18-002926 · primarydocument.xml · derivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-06 F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2014 Stock Option and Incentive Plan. The option will vest in full upon the earlier to occur of June 6, 2019 or the day immediately prior to the 2019 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date. Read SEC document |
| May 14, 2018 Filed May 16, 2018 16:35 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | GrantStock Option (Right to Purchase) · Derivative | 450,000 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0001192482-18-000223 · edgar.xml · derivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2028-05-14 F1 · derivative.exercise_date: The option award vests and becomes exercisable as follows (rounded up to the nearest whole share of common stock): one-third on May 14, 2019, then in 24 equal monthly installments on the 14th day of each subsequent calendar month, subject to the reporting person's continued service with the issuer. Read SEC document |
| October 17, 2017 Filed Oct 18, 2017 16:17 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | PurchaseWarrant (right to buy) · Derivative | 21,181 | $0.00 Strike: $2.84 | $0.00 |
DisclosureSEC source: 0001144204-17-053032 · tv477171_4.xml · derivative · entry 2 COLA MICHAEL F · CIK 0001188940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,181 Underlying: Common Stock · 21,181 shares Expires 2022-10-17 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.